The article by Morgan Dewitt et al1 concerning the effect of insurance coverage on the choice between etanercept and infliximab is an important addition to the effect of public policy on the delivery of medical care. I believe, however, that the authors have overemphasized the influence of the prescribing physician and have not taken into account modern practices of shared decision making with patients.
Sherrick RC. Etanercept or Infliximab: The Patient's Considerations. Arch Intern Med. 2006;166(13):1418. doi:10.1001/archinte.166.13.1418-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: